CADTH Reimbursement Recommendation Sodium-Glucose Cotransporter 2

59 Why Did CADTH Conduct This Review? 60 Publicly funded drug plans requested this Streamlined Drug Class Review of 61 SGLT2 inhibitors given the emergence of new evidence in cardiorenal 62 benefits and the loss of exclusivity of drugs within the class. [...] They also stressed the significance of the impact 72 of diet and flexibility of treatment options on their quality of life. [...] All outcomes have been between SGLT2 inhibitors and GLP-1 rated for the certainty of evidence following the GRADE agonists, sulfonylureas, DPP-4 approach and the review followed the established inhibitors, and basal insulins? protocol described in the publication. [...] 123 Given the role basal insulins play in the management of type 2 diabetes and 124 the uncertainty in cost associated with its use, the committee was unable to 125 determine the location 126 of basal insulins on the 127 decision plane. [...] 179 This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this 180 document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada 181 applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, 182 Canada.